ACELYRIN, INC. Common Stock (SLRN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ACELYRIN, INC. Common Stock (SLRN) has a cash flow conversion efficiency ratio of -0.096x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.95 Million) by net assets ($407.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ACELYRIN, INC. Common Stock net asset quality index to measure how much of total assets are equity-financed.
ACELYRIN, INC. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how ACELYRIN, INC. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore ACELYRIN, INC. Common Stock (SLRN) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
ACELYRIN, INC. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ACELYRIN, INC. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Forcecon Technology Co Ltd
TWO:3483
|
0.030x |
|
Squirrel Media SA
MC:SQRL
|
0.076x |
|
Xxentria Technology Materials Co Ltd
TWO:8942
|
0.008x |
|
Woori Technology Investment Co. Ltd
KQ:041190
|
0.000x |
|
Petron Malaysia Refining Marketing
KLSE:3042
|
0.135x |
|
Ledesma SAAI
BA:LEDE
|
0.123x |
|
Hawthorn Bancshares Inc
NASDAQ:HWBK
|
0.087x |
|
Jeju Air Co Ltd
KO:089590
|
0.262x |
Annual Cash Flow Conversion Efficiency for ACELYRIN, INC. Common Stock (2021–2024)
The table below shows the annual cash flow conversion efficiency of ACELYRIN, INC. Common Stock from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see ACELYRIN, INC. Common Stock market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $458.29 Million | $-303.92 Million | -0.663x | -156.48% |
| 2023-12-31 | $656.34 Million | $-169.71 Million | -0.259x | -146.82% |
| 2022-12-31 | $-111.39 Million | $-61.52 Million | 0.552x | +366.50% |
| 2021-12-31 | $-42.06 Million | $-4.98 Million | 0.118x | -- |
About ACELYRIN, INC. Common Stock
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorp… Read more